Archives 2026

SEDEMAC Mechatronics Limited’s initial public offering to open on Wednesday, March 04, 2026

SEDEMAC Mechatronics Limited’s initial public offering to open on Wednesday, March 04, 2026

Chandigarh, Feb 28: SEDEMAC Mechatronics Limited (the “Company”) proposes to open an initial public offering (“Offer”) of its equity shares of face value of ₹10 each (“Equity Shares”) on Wednesday, March 04, 2026. The Anchor Investor Bidding Date is one Working Day before the Bid/Offer Opening Date, being Monday, March 02, 2026. The Bid/ Offer Closing Date is Friday, March 06, 2026.

The Price Band of the Offer has been fixed from ₹1287 per Equity Shsare of face value ₹10 each to ₹1352 per Equity Share of face value ₹10 each. Bids can be made for a minimum of 11 Equity Shares of face value ₹10 each and multiples of 11 Equity Shares of face value ₹10 each thereafter.

The offer comprises an offer for sale of up to 8,043,300 Equity Shares of face value ₹10 each by existing promoter & promoter group selling shareholders, viz. Manish Sharma, and Ashwini Amit Dixit, and existing investor selling shareholders, viz. A91 Emerging Fund II LLP, NRJN Family Trust (represented by Entrust Family Office Legal & Trusteeship Services Private Limited), Xponentia Opportunities Fund II, Mace Private Limited, 360 One Special Opportunities Fund –  Series 8, 360 One Monopolistic Market Intermediaries Fund, HDFC Life Insurance Company Limited, Xponentia Opportunities Limited, Society for Innovation and Entrepreneurship, Cyrus Jamshed Guzde, Capri Global Holdings Private Limited, SVS Trust No IV, Venktesh Investment and Trading Company Private Limited, Himanshu Kantilal Sanghavi HUF, Devang Mehta, Atul Hiralal Shah, Bakul Hiralal Shah, Devinjit Singh, Perumal Ramamurthy Srinivasan, Bhavya Kapoor, and Rahul Bahri.

This offer includes a reservation of up to [●] equity shares of face value of ₹ 10 each, aggregating up to ₹10.00 million (constituting up to [●] % of the post-offer paid-up equity share capital) for subscription by eligible Employees (employee reservation portion).

A discount of ₹128 per Equity share is being offered to Eligible Employees bidding in the Employee Reservation Portion.

Founded in 2007 by four IIT Bombay engineers, SEDEMAC Mechatronics has grown into a globally deployed control technology company and one of the few Indian-origin suppliers to repeatedly deliver scalable, breakthrough innovations in automotive and industrial electronics.

The company is a leading supplier of control-intensive Electronic Control Units (ECUs) to major OEMs across India, the United States, and Europe. With fully in-house proprietary control technology capabilities, SEDEMAC serves two- and three-wheelers, electric vehicles, and generator applications.

Strategically, the company is expanding into commercial vehicles and the power tools segment, with successful proof-of-concept demonstrations in sensorless motor control and ongoing development of ECUs for commercial vehicle platforms — positioning it for the next phase of growth

This Offer is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process and is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”) provided that the  Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which at least 40% shall be reserved for domestic Mutual Funds, Life Insurance Companies and Pension Funds, in the following manner (i) 33.33% shall be reserved for domestic Mutual Funds; and (ii) 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, the balance Equity Shares shall be available for allocation to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations (“Retail Portion”), subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

Further, all potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Offer.

The Equity Shares of the Company are proposed to be listed on BSE Limited (BSE) and the National Stock Exchange of India Limited (NSE) (BSE and NSE together, the Stock Exchanges).  

ICICI Securities Limited, Avendus Capital Private Limited and Axis Capital Limited are the Book Running Lead Managers (BRLMs) to the Offer.

All capitalised terms not defined herein would have the same meaning as attributed to them in the RHP.

MAHE Marks National Science Day 2026 with Focus on Science, Sustainability, and Innovation

MAHE Marks National Science Day 2026 with Focus on Science, Sustainability, and Innovation

Manipal, Feb 28: Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, will organise the National Science Day Celebrations 2026 on Saturday, February 28, at the Dr TMA Pai Auditorium, 3rd Floor, KMC, Manipal. The chief guest for the programme will be

Dr Hoysall N. Chanakya, Chief Research Scientist (Retd.), Centre for Sustainable Technologies, Indian Institute of Science (IISc), Bengaluru. A distinguished scientist and thought leader in sustainable technologies, Dr Chanakya has over four decades of research experience and has guided more than 10 doctoral scholars and over 20 postgraduate research students, and has led over 50 research, development, and consultancy projects. Since 1978, his work has focused on decentralised bioenergy technologies, including biogas plants and related systems, energy integration into rural livelihoods, water and wastewater purification, and the restoration of water bodies. The event will be presided over by Dr H S Ballal, Pro Chancellor, MAHE, whose leadership has been instrumental in strengthening MAHE’s academic and research ecosystem. 

The celebrations will be graced by senior MAHE leadership, including Dr Narayana Sabhahit, Pro Vice Chancellor – Technology and ScienceMAHE, Dr P. Giridhar Kini, Registrar, MAHE, and Dr Anil K. Bhat, Dean, Kasturba Medical College (KMC), Manipal. 

National Science Day is observed across India to commemorate Sir C. V. Raman’s discovery of the Raman Effect. MAHE encourages young minds to adopt a scientific approach to life and society. 

Rohde & Schwarz and Viasat to collaborate on NB-NTN IoT test plan for connectivity via satellite

Feb 28: Viasat and Rohde & Schwarz have joined forces to boost testing for Narrowband Non-terrestrial Networks (NB-NTN) IoT devices connecting via satellite. By thoroughly validating devices and confirming interoperability with Viasat’s network, the collaboration aims to help ensure uninterrupted connectivity for a wide range of satellite-based Internet of Things (IoT) applications. Visitors to MWC Barcelona 2026 can experience the test plan in action.
 

 The test plan with Viasat runs on the CMX500 one-box tester for NTN testing.

Viasat, a global leader in satellite communications, and Rohde & Schwarz, a leading provider of test and measurement solutions, are working together to strengthen and expand testing for Non Terrestrial Network (NTN) capabilities, specifically for NB-IoT devices. The collaboration aims to ensure that chipsets, modules and devices interoperate seamlessly with Viasat’s satellite network and comply with 3GPP Release 17 standards.

Deploying advanced testing methodologies upholds the highest standards of quality, performance and reliability for Viasat’s connectivity services: delivering ubiquitous IoT applications in areas without terrestrial network coverage.

The certification test plan with Viasat entails protocol, performance and RF test scenarios. It is based on the CMX500 one-box signaling tester from Rohde & Schwarz, a versatile solution designed for testing various NTN technologies, including New Radio (NR-NTN) and NB-NTN. In a single instrument, the CMX500 covers R&D through certification and carrier acceptance tests, guaranteeing reliable and repeatable results. It empowers engineers to accelerate development, ensure quality and confidently deploy reliable NTN services, safeguarding that the whole ecosystem can achieve the highest levels of performance.

Rohde & Schwarz will showcase first test results covering protocol, performance and RF test scenarios of the test plan at the Rohde & Schwarz booth 5A80 in hall 5 from March 2 to 5, 2026 at MWC Barcelona 2026. Visit Viasat in hall 6, booth 6A20.

KIRIN HYOKETSU Expands into U.S. RTD Market with Local Production

Business Wire India

 

New Belgium Brewing, the Kirin Group company leading its U.S. alcoholic beverage business, will launch two original flavors KIRIN HYOKETSU STRAWBERRY and KIRIN HYOKETSU PINEAPPLE under the KIRIN HYOKETSU (HYOKETSU) brand, manufactured and sold by Kirin Brewery Company, Limited (Kirin Brewery). The ready to drink cocktail will be available in Hawaii, Tampa, FL, and The Japan Pavilion at EPCOT theme park, operated by Mitsukoshi (U.S.A.), on March 2.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227374991/en/

 

 

KIRIN HYOKETSU STRAWBERRY and KIRIN HYOKETSU PINEAPPLE

KIRIN HYOKETSU STRAWBERRY and KIRIN HYOKETSU PINEAPPLE

 

 

Created with American consumers in mind, the new flavors bring HYOKETSU’s signature crisp, fruit-forward taste to two key U.S. markets. Produced and sold locally in the U.S., the beverages deliver fresh fruit flavor in a convenient, easy-to-enjoy format.

 

The U.S. is the world’s largest ready-to-drink (RTD) market, accounting for approximately half of the global market*1. Fruit-forward flavors and convenience continue to make RTDs one of the fastest-growing segments in the category.

 

 

*1

IWSR (2024)

 

Since its launch in 2001, HYOKETSU has become one of Japan’s leading RTD brands, known for its crisp, fruit-forward profile. In Japan, the brand has sold a cumulative total of approximately 15 billion units*2, reflecting long-term consumer demand and brand strength.

 

*2

350ml equivalent basis, as of December 31, 2025.

 

Through local manufacturing and sales in the U.S., Kirin Brewery seeks to deliver fresh fruit flavor in a convenient format while building HYOKETSU as a scalable global brand.

 

 

 

Product Details

 

Product

 

 

  • Strawberry and Pineapple, two flavors popular with U.S. consumers were selected for the launch.
  • Designed for American tastes, the RTDs deliver HYOKETSU’s signature fruit-forward profile, with fresh fruit flavor and a light, easy-to-drink finish.

 

 

Package Design

 

  • Packaging features HYOKETSU’s signature blue and silver color palette, signaling freshness and fruit character.
  • The “KIRIN” and HYOKETSU brand names are clearly displayed, while the “CHU-HI” description references the product’s Japanese roots.

 

 

About Kirin Holdings

 

Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain.

 

 

Under its long-term vision “Innovate2035!”, the Kirin Group is focused on creating value that encourage behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being.

 

 

The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*, while pursuing sustainable, long-term growth in corporate value.

 

 

*Creating Shared Value: combined added value for consumers as well as for society at large.

 

 

 

 

 

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Business Wire India

 

  • IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161.
  • IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK.
  • First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement.

 

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen.

 

According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances.

 

 

IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. IDEAYA has stated that IDE034 is designed to preferentially internalize in tumor cells co-expressing B7H3 and PTK7, supporting selectivity and tolerability, and estimates 30–40% co-expression across several major solid tumors with limited dual expression in normal tissues.

 

 

“Reaching first dosing in the IDE034 Phase 1 trial marks an important step in translating this bispecific TOP1 ADC concept into clinical evaluation,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “We appreciate IDEAYA’s strong execution in advancing IDE034 into the clinic and look forward to the readout of initial safety and PK data from the ongoing Phase 1 study.”

 

 

About Biocytogen

 

 

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

 

 

Biocytogen has independently developed its proprietary RenMice® (RenMab®/ RenLite®/ RenNano®/RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

 

 

 

 

 

Omdia: Xiaomi Reclaims Wearable Band Crown for the First Time Since 2020

Business Wire India

 

Global wearable device shipments climbed past 200 million units in 2025, growing 6% year on year according to Omdia. Xiaomi has reclaimed the top spot for the first time since 2020, capturing an 18% market share to become the world’s largest wearable vendor by annual shipments. Apple followed closely in second place with 17%, while Huawei secured third with 16%. The market is also seeing increased consolidation, with the top five vendors, including Samsung (9%) and Garmin (5%), with the top three in a tight race.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227981313/en/

 

 

Global wearable band market share, by category, 2024-2025

Global wearable band market share, by category, 2024-2025

 

 

“Wearables are moving from a hardware-driven race to an ecosystem-led competition,” said Omdia Research Manager Cynthia Chen. “With less than one percentage point separating the top three vendors, competitive advantage now depends on seamless cross-device integration and the ability to deliver monetizable, value-added data services.” Xiaomi’s rise reflects a structured multi-category strategy rather than reliance on a single flagship product. Its bands continue to anchor volume in the mass market, while its basic watches, supported by in-house chip development and deeper ecosystem integration, are enabling the brand to move up the value chain. Apple retains a strong premium position, leveraging 5G connectivity and advanced health features, including hypertension monitoring, to sustain high loyalty among its high-value users. Huawei has consolidated its mainstream presence through a broad portfolio, while intensifying its focus on professional sports and medical-grade health applications.

 

AI and subscription services are reshaping competition, transforming from nice-to-have features into essential revenue drivers of growth and profitability. Wearable bands are increasingly optimized for continuous health monitoring, with some vendors exploring screenless or reduced-screen designs to improve comfort and data continuity. “The wearables profit model is undergoing structural change,” said Omdia Research Director Jason Low. “Algorithms and services are becoming standalone profit centers, with advanced health insights, professional training plans, and AI-powered coaching generating recurring subscription revenue.” For vendors with a higher-priced portfolio, subscription services represent more than just additional revenue. They are becoming essential to maintaining profitability as hardware margins compress due to rising component costs. This recurring revenue model provides a critical buffer against the volatility of hardware pricing. Meanwhile, improved insights into health and sport tracking are designed to increase usage and stickiness, which, in turn, provides more data points for more tailored services.

 

 

Looking ahead, Omdia expects the global wearables market to deliver modest single-digit growth in 2026, reflecting not only continued expansion in shipment volume but also a gradual shift in industry value dynamics. Growth will increasingly be driven by on-device AI advancements and the rising demand for more professional-grade sports and health management. Meaningful upgrade cycles will rely on real breakthroughs in substantive health monitoring capabilities. For leading smartwatch vendors, such as Apple, Samsung, and Huawei, progress in key physiological metrics, particularly blood glucose and blood pressure monitoring, will become the primary catalyst for renewed growth. Among the three major categories, smartwatches are expected to show the strongest momentum, combining advanced sensing, AI analytics, and deeper ecosystem connectivity to serve as the most scalable platform for AI agent integration. At the same time, improving subscription and service monetization is strengthening profitability and enabling reinvestment in technology and ecosystem development. Over time, competitive advantage will depend less on shipment scale alone and more on the depth of AI capability and the strength of cross-device ecosystem integration.

 

 

Worldwide wearable band market share split
Omdia Preliminary Wearable Band Market Pulse: 2025

 
             

Vendor

 

 

2025
market
share

 

 

2024
market
share

 

 

Xiaomi

 

 

18%

 

15%

 

Apple

 

 

17%

 

18%

 

Huawei

 

 

16%

 

14%

 

Samsung

 

 

9%

 

8%

 

Garmin

 

 

5%

 

4%

 

Others

 

 

35%

 

41%

 

 

 

 

 

 

 

 

 

 

 

 

Note: Preliminary estimates are subject to change on final release
Xiaomi includes Redmi and POCO, vivo includes iQOO, OPPO includes OnePlus
Source: Omdia Wearable Tech Service (sell-in shipments), Feb 2026

 

 

 

ABOUT OMDIA

 

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, makes our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

 

 

 

 

 

Cosmo Speciality Chemicals Announces Launch of Advanced Masterbatches Portfolio

Cosmo Speciality Chemicals Announces Launch of Advanced Masterbatches Portfolio

Chandigarh, Feb 28: Cosmo Speciality Chemicals, a subsidiary of Cosmo First Limited, has announced the launch of its expanded range of high-performance masterbatches, further strengthening its Specialty Chemicals portfolio and reinforcing its presence in value-added polymer solutions.

The newly introduced portfolio includes CosmoWhite, a premium portfolio of advanced white masterbatches for polypropylene (PP) and polyethylene (PE). Developed with high concentrations of Titanium Dioxide (TiO₂), CosmoWhite provides exceptional opacity, brightness, UV protection, and thermal stability. These qualities ensure reliable performance in demanding applications such as BOPP films, blown films, extrusion coating, injection moulding, non-wovens, raffia, and pail containers.

In addition to this, Cosmo Speciality Chemicals has also unveiled CosmoAdd which is a complementary portfolio of additive masterbatches engineered to enhance processing efficiency, product durability, and end-use functionality. Tailored for flexible packaging in BOPP, CPP, and blown film applications, the CosmoAdd portfolio encompasses a wide range of solutions including cavitating agents (inorganic and organic), antiblock additives (inorganic and organic), antistatic and slip additives, polymer processing aids (standard and PFAS-free), antioxidants, clarifiers, matt compounds, and specialized solutions for synthetic paper. Additionally, CosmoAdd addresses industry challenges, reinforcing its role as a comprehensive and forward-looking portfolio for modern packaging needs.

Commenting on the launch, Mr. Raj Sharma, Business Head, Cosmo Speciality Chemicals, said, “Our expanded masterbatch portfolio reflects our focus on innovation-led specialty solutions. We remain committed to delivering high-performance, sustainable, and application-specific masterbatches that enhance both functionality and aesthetics for our customers across the polymer and packaging industry. Together, CosmoWhite and CosmoAdd embody Cosmo Speciality Chemicals’ commitment to delivering engineered excellence and practical innovation, ensuring manufacturers achieve superior product quality, efficiency, and sustainability.” 

This development is closely aligned with Cosmo First’s strategy of expanding its Specialty Chemicals vertical, which has been steadily scaling alongside its core specialty films business. Initiated in FY21, the specialty chemicals division operates with strong R&D capabilities and continues to build a growing presence in external markets.

With this launchCosmo Speciality Chemicals reinforces its position as a trusted Indian manufacturer of innovation-driven masterbatch solutions, offering tailored formulations backed by rigorous research, advanced technology, and sustainable manufacturing practices.

Star Union Dai-ichi Life Insurance Expands Insurance Outreach in Goa

Advancing financial protection across communities in GoaStar Union Daiichi Life Insurance (SUD Life), the Lead Insurer for the state, engaged more than 2,000 members in 20 Gram Panchayats through a focused awareness initiative held in Jan – February 2026 under the State Insurance Plan.

The Insurance Awareness Campaign focused on building awareness about the importance of life insurance protection and encouraging enrolment under the Pradhan Mantri Jeevan Jyoti Bima Yojana (PMJJBY). Structured Panchayat-level seminars and interactive Q&A sessions were conducted across North and South Goa districts to improve understanding of affordable life insurance solutions.

The programme saw active participation from Gram Mukhiyas, Gram Sachivs and Sarpanches, whose support was instrumental in mobilising villagers and encouraging active community participation. Their involvement helped reinforce the importance of financial protection at the grassroots level and built greater trust within the local communities.

Financial concepts were simplified through insurance themed interactive games, while queries were clarified and misconceptions removed, empowering families to make informed financial decisions.

Founded in 2009, SUD Life has served over 15 million customers across India through sustained efforts, grassroots outreach and insurance awareness programmes, contributing to an improved financial protection coverage.

Commenting on the initiative, Shri. Abhay Tewari, MD & CEO Star Union Daiichi Life Insurance said, “Community-led insurance awareness is essential to enhancing financial security at the grassroots. The encouraging participation we received in Goa reflects the growing awareness about the need for life insurance protection. We will continue working closely with Panchayat leaders and local communities to improve access to affordable schemes like PMJJBY, strengthen insurance coverage across the state, and achieve the Government’s vision of Insurance for All by 2047.”

Aligned with its core philosophy of “Protecting Families, Enriching Lives,” Star Union Daiichi Life Insurance continues to strengthen financial inclusion initiatives and deepen insurance penetration across rural Goa through sustained grassroots outreach.

NSDC Expands Centre for Future Skills Initiative to Embed Global Certifications within Higher Education

Chandigarh, Feb 28: The National Skill Development Corporation (NSDC) is strengthening India’s higher education and skilling ecosystem through the expansion of its flagship Centre for Future Skills (CFS) initiative — a campus-based, technology-integrated model designed to embed advanced technical training, global certifications, and hands-on project learning directly into mainstream degree programmes. Conceived as a long-term national intervention, the initiative aims to impact one million students over the next decade by aligning academic pathways with globally benchmarked industry standards and emerging technology demands.

The Centre for Future Skills model has already been operationalised across multiple institutions nationwide, with training activities actively underway at each location. The initiative has begun creating tangible impact by equipping students with industry-aligned competencies embedded within their academic journey.

Speaking on the initiativeShri Arunkumar Pillai, CEO, NSDC, said, “The Centre for Future Skills marks a structural shift in how India prepares its youth for the future economy. It is already demonstrating impact at scale with its 12 operational institutions and over 43,000 trained candidates. Over the next three years, we aim to add 22 more centres nationwide. With the integration of global certifications and hands-on learning within degrees, we are ensuring graduates enter the workforce industry-ready and globally benchmarked.”

The inauguration of a new Centre at the Federal Institute of Science and Technology (FISAT), Kochi, marks another step in this national rollout, reinforcing the broader vision of institutional transformation.

The Centre for Future Skills operates as an on-campus hub that integrates academic credit pathways, industry-recognised certifications, expert mentorship, and state-of-the-art laboratory infrastructure. Students earn two to three academic credits per semester alongside globally recognised certifications without extending the duration of their degree, enabling a dual outcome — a university qualification coupled with validated employability credentials. The model ensures that structured skill pathways are woven into the academic journey itself.

Through partnerships with leading global technology companies, CFS provides access to over 200 certification programmes across high-growth domains. These certifications are delivered at significantly subsidised costs compared to prevailing market rates, expanding access to world-class, industry-relevant technical education. Students who successfully complete assessments receive globally recognised credentials that enhance mobility across both domestic and international job markets.

A defining feature of the CFS framework is its structured, multi-semester skill pathways that progressively build technical competence aligned with industry demand. For example, under the Software Engineering track, learners advance from programming foundations to full-stack development, cloud deployment, and software engineering practices. By graduation, students may earn four to six global certifications while building strong project portfolios and gaining hands-on experience in cloud, DevOps, and application development environments. Importantly, pathways are structured for both technical and non-technical learners, enabling interdisciplinary participation in emerging technology areas.

The infrastructure-led approach under CFS further reinforces its impact. NSDC establishes advanced hardware and software laboratories within partner institutions. Each certification course runs for 45 to 50 hours per semester and is delivered in physical mode through lab sessions, projects, and rigorous assessments, ensuring quality and practical immersion. At FISAT, the Centre is projected to enrol approximately 3,500 students per semester, or 7,000 students annually, reflecting the scalable and large-scale nature of the initiative.

At a systemic level, the Centre for Future Skills introduces what NSDC describes as a “Global Certification Stack,” effectively internationalising Indian talent. By embedding globally benchmarked certifications within degrees, the initiative enhances signalling power in the labour market, reduces industry training burdens through validated skill credentials, and strengthens India’s positioning within global talent supply chains. The degree, under this model, evolves from being a knowledge credential to becoming a productivity indicator aligned with future industry needs.

As India accelerates its transition towards a knowledge and innovation-led economy, the expansion of the Centre for Future Skills signals a decisive move to embed employability, technology readiness, and global competitiveness within the country’s higher education architecture.

Bloated, Moody, Exhausted? These Five Gut Essentials Could Be the Missing Link

New Delhi, Feb 28: If your skin is acting up, your mood feels unpredictable, and your energy crashes before the day ends, the answer may lie deeper than stress or lack of sleep. Emerging scientific research increasingly highlights the powerful gut-brain-heart axis a fully connected system where gut bacteria influence digestion, immunity, hormones, heart function, and even emotional wellbeing.

The gut produces nearly 90–95% of serotonin, the hormone responsible for mood, sleep, and emotional balance, and houses 70–80% of the immune system. When gut health is compromised, inflammation can disrupt hormones, weaken immunity, trigger brain fog, and even lead to skin flare-ups. Simply put, when the gut is off balance, the entire body feels it.

Recognising the growing awareness around digestive health, we highlight five gut health supplements designed to help restore microbial balance, improve digestion, and strengthen overall wellbeing.

Five Gut Health Essentials Worth Adding to Your Routine

1. LivLively – Gut Restore Blend

Rooted in natural ingredients and backed by clinical research, LivLively’s Gut Restore Blend features Amla and Green Tea leaf extract to support microbiome balance. The formula is designed to address bloating, acidity, low energy, and sleep concerns by supporting melatonin balance. Ideal for those who prefer a holistic, food-science-driven approach to gut health.

Available at: livlively.in

2. The Good Bug – Healthy Gut Balance

Designed as a daily gut reset, this supplement combines clinically studied probiotic strains — Lacticaseibacillus rhamnosus LGG® and Bifidobacterium lactis BB-12® — with prebiotics to restore microbial diversity. It targets bloating, erratic digestion, gas, and immune support, offering a clean, science-led formulation.

Available at: thegoodbug.com

3. Tata 1mg – Probiotics 30 Billion CFUs with Prebiotic Fibre

For those requiring intensive gut support, this capsule delivers 30 billion CFUs across 14 probiotic strains, combined with prebiotic fibre to nourish beneficial bacteria. Non-GMO and preservative-free, it is particularly suited for post-antibiotic recovery and digestive reinforcement.

Available at: 1mg.com

4. Wellbeing Nutrition – Melts Healthy Gut Oral Strips

A modern alternative to capsules, these fast-dissolving oral strips combine probiotics with Apple Cider Vinegar to support digestion, metabolism, and bowel regularity. Travel-friendly and easy to use, they are ideal for individuals who prefer pill-free supplementation.

Available at: wellbeingnutrition.com

5. Inlife Healthcare – Pre + Probiotic Capsules

A simple and affordable option, these gluten-free and non-GMO capsules combine probiotics with prebiotic fibre to support digestion, nutrient absorption, and overall microbiome balance. Suitable for those beginning their gut health journey.

Available at: inlifehealthcare.com

The Bottom Line

Gut health is not a fleeting wellness trend — it is central to immune function, hormonal balance, mental clarity, and overall vitality. Whether you are dealing with bloating, low energy, poor immunity, or mood fluctuations, supporting your gut microbiome could be one of the most impactful health decisions you make this year.

Consistency remains key. Choose the supplement that aligns with your needs and lifestyle, and allow your gut to restore balance from within.